

GPC3 Protein-VLP, Human, Recombinant

General Information

Synonyms:	Glypican 3;SGB;SGBS1SDYS;DGSX;OCI-5;OCI5;GTR2-2;GPC3;SGBS1;SGBS;MXR7;SDYS
Protein Construction:	Gly510-Asn554
Species:	Human
Expression Host:	E. coli
Accession:	P51654-1
Molecular Weight:	14 kDa (predicted)

QC Testing

Biological Activity:	Immobilized Human GPC3 VLP at 0.5µg/ml (100µl/Well) on the plate. Dose response curve for Anti-GPC3 Antibody, hFc Tag with the EC50 of 20.2ng/ml determined by ELISA.
Endotoxin:	< 1.0 EU/µg of the protein as determined by the LAL method.
Formulation:	Supplied as 0.22 µm filtered solution in 20 mM HEPES, 500 mM NaCl, 10% Glycerol, 0.1% Tween20 (pH 7.7).

Preparation and Storage

Stability & Storage:

It is recommended to store the product under sterile conditions at -70°C or lower. Samples are stable for up to 12 months at -80°C. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

Shipping:

Proteins are shipped with blue ice.

Protein Background

Glypican-3 is a protein, which is encoded by the GPC3 gene in humans. The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa. Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed.

Reference

Ho M, Kim H. Glypican-3: A new target for cancer immunotherapy[J]. European Journal of Cancer, 2011, 47(3):0-338.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481